Efeito antifúngico do fosmanogepix frente a infecções causados por Candida auris: uma revisão da literatura

Abstract

Resistant microorganisms poses a challenge to the treatment of infections, limiting therapeutic drug options. Some fungal species, such as Candida auris, have shown resistance to the major classes of antifungals available. Fosmanogepix is a new drug candidate for the treatment of infections caused by C. auris, and is currently undergoing phase 2 clinical trials seeking approval by the Food and Drug Administration (FDA). This study aimed to analyze the information available in the literature to verify whether fosmanogepix has antifungal activity against infections caused by C. auris. Data used for this analysis were obtained from articles available on the PubMed and Google Scholar platforms from 2018 to 2023. When compared to other antifungal agents, fosmanogepix showed the best in vitro susceptibility results against C. auris isolates, with lower Minimum Inhibitory Concentration (MIC) values, indicating antifungal action even at low concentrations. In vivo studies using mice demonstrated increased survival with fosmanogepix treatment compared to anidulafungin treatment. No adverse effects were reported during the phase 2 clinical trial. It was concluded, therefore, that fosmanogepix had in vitro antifungal activity against C. auris colonies and other microorganisms. Regarding in vivo activity, treatment with the antifungal in question is well tolerated, safe, and effective against infections caused by C. auris. Fosmanogepix showed great potential to be a new therapeutic alternative against multidrug-resistant and pan-resistant fungi such as Candida auris.